102 filings
Page 4 of 6
8-K
xxm avv55by33yj
10 Apr 18
Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
qxuga01bzj
9 Apr 18
Departure of Directors or Certain Officers
12:00am
8-K
p53iz5bfue9k752fe
6 Mar 18
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
8glr h4xa8q9ztex
23 Feb 18
Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD
12:00am
8-K
s0e0w2r
12 Feb 18
Kadmon Announces Positive Topline Results from Phase 2 Study of KD025
12:00am
8-K
2qtyt
26 Dec 17
Other Events
12:00am
8-K
hfs28r
11 Dec 17
Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting
12:00am
8-K
idtr3hpk6j t904m3
11 Dec 17
Regulation FD Disclosure
12:00am
8-K
rh0 cd0qygsfzbx6
13 Nov 17
Other Events
12:00am
8-K
zc9h8opx
9 Nov 17
Kadmon Provides Business Update and Reports Third Quarter 2017 Financial Results
12:00am
8-K
7l7 hinub6my24r
6 Oct 17
Departure of Directors or Certain Officers
12:00am
8-K
i9eu9to3x3 grbl32
28 Sep 17
Kadmon Announces Pricing of Public Offerings of Common Stock and Warrants
12:00am
8-K
p9t9b8sjb1jv9qwsk
25 Sep 17
Kadmon Announces Proposed Public Offering of Common Stock and Warrants
12:00am
8-K
0ls45ae9
14 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
dtho7fz
3 Aug 17
Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results
12:00am
8-K
y9sjkx
25 Jul 17
Kadmon Announces Supplemental Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
akkwvhuwdq69ilyl5
11 Jul 17
Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host Disease
12:00am
8-K
ixtnj8a0fqb 42qrs1as
29 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3sccx25batp3yodwa
23 Jun 17
Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day
12:00am
8-K
6kxfjlee9lhgfrrw6
14 Jun 17
Departure of Directors or Certain Officers
12:00am